Quantum BioPharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
micro-palmitoylethanolamide (FSD-PEA) / Quantum BioPharma
NCT05652907: Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

Terminated
2
2
Canada, US
FSD201, Placebo
FSD Pharma, Inc.
Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic
05/23
05/23
ACTRN12620000213943p: A Phase 1 study to evaluate Safety, Tolerability and Pharmacokinetics of Ultramicronized-Palmitoylethanolamide (PEA) in Healthy Subjects.

Not yet recruiting
1
48
 
FSD Pharma Inc., FSD Pharma Inc.
Chronic Pain; Inflammation
 
 
LUCID-MS / Quantum BioPharma
NCT05821387: Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers

Completed
1
40
Canada
Lucid-21-302, Placebo
FSD Pharma, Inc., Lucid Psycheceuticals Inc. (sub of FSD Pharma, Inc.)
Healthy Participants
07/23
07/23
NCT06595706: Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants

Completed
1
16
RoW
Lucid-21-302, Placebo
Huge Biopharma Australia Pty Ltd, Huge Biopharma Australia Pty Ltd
Heathy Participants
01/25
01/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
micro-palmitoylethanolamide (FSD-PEA) / Quantum BioPharma
NCT05652907: Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

Terminated
2
2
Canada, US
FSD201, Placebo
FSD Pharma, Inc.
Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic
05/23
05/23
ACTRN12620000213943p: A Phase 1 study to evaluate Safety, Tolerability and Pharmacokinetics of Ultramicronized-Palmitoylethanolamide (PEA) in Healthy Subjects.

Not yet recruiting
1
48
 
FSD Pharma Inc., FSD Pharma Inc.
Chronic Pain; Inflammation
 
 
LUCID-MS / Quantum BioPharma
NCT05821387: Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers

Completed
1
40
Canada
Lucid-21-302, Placebo
FSD Pharma, Inc., Lucid Psycheceuticals Inc. (sub of FSD Pharma, Inc.)
Healthy Participants
07/23
07/23
NCT06595706: Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants

Completed
1
16
RoW
Lucid-21-302, Placebo
Huge Biopharma Australia Pty Ltd, Huge Biopharma Australia Pty Ltd
Heathy Participants
01/25
01/25

Download Options